<DOC>
	<DOCNO>NCT02070978</DOCNO>
	<brief_summary>This multicenter , double-blind , Phase 2b , long-term extension ( LTE ) ADDRESS II core trial ( EMR 700461-023 ) ( NCT01972568 ) , evaluate long-term safety tolerability atacicept subject systemic lupus erythematosus ( SLE ) . The Week 24 visit ADDRESS II core trial coincide Day 1 visit LTE trial .</brief_summary>
	<brief_title>Long-term Safety Tolerability Atacicept ( Long-term Follow-Up Patients Who Participated ADDRESS II )</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Subjects complete 24week treatment period trial EMR700461023 ( ADDRESS II core trial ) Women childbearing potential negative pregnancy test Other protocol define inclusion criterion could apply Active neurological symptom SLE deem severe progressive Diagnosis demyelinate disease , , restrict , multiple sclerosis ( MS ) optic neuritis Pregnancy Active clinically significant viral , bacterial , fungal infection , major episode infection investigator 's opinion make subject unsuitable continue participation trial Other protocol define exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Lupus Erythematosus , Systemic</keyword>
	<keyword>Atacicept 75 150 mg</keyword>
	<keyword>LTE</keyword>
</DOC>